A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results.

AIM Physiologically based toxicokinetic (PBTK) models are computational tools, which simulate the absorption, distribution, metabolism, and excretion of chemicals. The purpose of this study was to develop a physiologically based pharmacokinetic (PBPK) model with a high level of transparency. The model should be able to predict blood and urine concentrations of environmental chemicals and metabolites, given a certain environmental or occupational exposure scenario. MODEL The model refers to a reference human of 70 kg. The partition coefficients of the parent compound and its metabolites (blood:air and tissue:blood partition coefficients of 11 organs) are estimated by means of quantitative structure-property relationship, in which five easily available physicochemical properties of the compound are the independent parameters. The model gives a prediction of the fate of the compound, based on easily available chemical properties; therefore, it can be applied as a generic model applicable to multiple compounds. Three routes of uptake are considered (inhalation, dermal, and/or oral) as well as two built-in exercise levels (at rest and at light work). Dermal uptake is estimated by the use of a dermal diffusion-based module that considers dermal deposition rate and duration of deposition. Moreover, evaporation during skin contact is fully accounted for and related to the volatility of the substance. Saturable metabolism according to Michaelis-Menten kinetics can be modelled in any of 11 organs/tissues or in liver only. Renal tubular resorption is based on a built-in algorithm, dependent on the (log) octanol:water partition coefficient. Enterohepatic circulation is optional at a user-defined rate. The generic PBTK model is available as a spreadsheet application in MS Excel. The differential equations of the model are programmed in Visual Basic. Output is presented as numerical listing over time in tabular form and in graphs. The MS Excel application of the PBTK model is available as freeware. EXPERIMENTAL The accuracy of the model prediction is illustrated by simulating experimental observations. Published experimental inhalation and dermal exposure studies on a series of different chemicals (pyrene, N-methyl-pyrrolidone, methyl-tert-butylether, heptane, 2-butoxyethanol, and ethanol) were selected to compare the observed data with the model-simulated data. The examples show that the model-predicted concentrations in blood and/or urine after inhalation and/or transdermal uptake have an accuracy of within an order of magnitude. CONCLUSIONS It is advocated that this PBTK model, called IndusChemFate, is suitable for 'first tier assessments' and for early explorations of the fate of chemicals and/or metabolites in the human body. The availability of a simple model with a minimum burden of input information on the parent compound and its metabolites might be a stimulation to apply PBTK modelling more often in the field of biomonitoring and exposure science.

[1]  M. Szutowski,et al.  Multiplicity of n‐heptane oxidation pathways catalyzed by cytochrome P450 , 2009, Journal of biochemical and molecular toxicology.

[2]  S Haddad,et al.  A methodology for solving physiologically based pharmacokinetic models without the use of simulation softwares. , 1996, Toxicology letters.

[3]  J. Taskinen,et al.  Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  David M. Umulis,et al.  A physiologically based model for ethanol and acetaldehyde metabolism in human beings. , 2005, Alcohol.

[5]  Christoph van Thriel,et al.  Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  M E Andersen,et al.  A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. , 1984, Toxicology and applied pharmacology.

[7]  R A Corley,et al.  Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.

[8]  W. Dekant,et al.  A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[9]  K. Krishnan,et al.  Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. , 2005, Chemical research in toxicology.

[10]  Thomas Peyret,et al.  A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. , 2010, Toxicology and applied pharmacology.

[11]  A. Bunge,et al.  Physiologically relevant two-compartment pharmacokinetic models for skin. , 2000, Journal of pharmaceutical sciences.

[12]  D. Levitt.  PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol , 2002, BMC clinical pharmacology.

[13]  T E McKone,et al.  Estimating skin permeation. The validation of five mathematical skin permeation models. , 1995, Chemosphere.

[14]  W. ten Berge,et al.  A simple dermal absorption model: derivation and application. , 2009, Chemosphere.

[15]  S. Borghoff,et al.  Physiologically based pharmacokinetic model of methyl tertiary butyl ether and tertiary butyl alcohol dosimetry in male rats based on binding to alpha2u-globulin. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  R. Gehring,et al.  A physiologically based pharmacokinetic model of organophosphate dermal absorption. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  Bruce A. Pearce,et al.  Windows® based general PBPK/PD modeling software , 2008, Comput. Biol. Medicine.

[18]  R Tardif,et al.  Physiological modeling of the toxicokinetic interactions in a quaternary mixture of aromatic hydrocarbons. , 1999, Toxicology and applied pharmacology.

[19]  W. Dekant,et al.  Biotransformation and kinetics of excretion of ethyl tert-butyl ether in rats and humans. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[20]  G. E. Searle,et al.  APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN RAT PLASMA , 2006, Drug Metabolism and Disposition.

[21]  J Bahima,et al.  Identification of volatile metabolites of inhaled n-heptane in rat urine. , 1984, Toxicology and applied pharmacology.

[22]  G. B. Bartolucci,et al.  Identification of the n-heptane metabolites in rat and human urine , 1986, Archives of Toxicology.

[23]  R A Corley,et al.  Physiologically based pharmacokinetic modeling of the temperature-dependent dermal absorption of chloroform by humans following bath water exposures. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  R. Moon,et al.  Ventilation-perfusion inequality in normal humans during exercise at sea level and simulated altitude. , 1985, Journal of applied physiology.

[25]  D. R. White,et al.  The composition of body tissues. , 1986, The British journal of radiology.

[26]  H J Clewell,et al.  Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.

[27]  W. Dekant,et al.  Biotransformation and kinetics of excretion of methyl-tert-butyl ether in rats and humans. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[28]  F. Jongeneelen,et al.  Biological Versus Ambient Exposure Monitoring of Creosote Facility Workers , 2002, Journal of occupational and environmental medicine.

[29]  G Maranelli,et al.  Partition coefficients of some industrial aliphatic hydrocarbons (C5-C7) in blood and human tissues. , 1985, British journal of industrial medicine.

[30]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.

[31]  Gunnar Johanson,et al.  The Use of Biokinetics and in Vitro Methods in Toxicological Risk Evaluation , 1996 .

[32]  R Tardif,et al.  Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. , 2000, Toxicology and applied pharmacology.

[33]  M. Reddy,et al.  Physiologically relevant one-compartment pharmacokinetic models for skin. 2. Comparison of models when combined with a systemic pharmacokinetic model. , 1998, Journal of pharmaceutical sciences.

[34]  J. A. Bond,et al.  Disposition of three glycol ethers administered in drinking water to male F344/N rats. , 1990, Toxicology and applied pharmacology.

[35]  G. Johanson,et al.  Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. , 1986, Toxicology letters.

[36]  Guidance on information requirements and chemical safety assessment , 2008 .

[37]  W. Dekant,et al.  Toxicokinetics of methyl tert-butyl ether and its metabolites in humans after oral exposure. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  Melvin E Andersen,et al.  Modeling of human dermal absorption of octamethylcyclotetrasiloxane (D(4)) and decamethylcyclopentasiloxane (D(5)). , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  H J Clewell,et al.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. , 2000, Environmental health perspectives.

[40]  McCarley,et al.  Physiologically relevant one-compartment pharmacokinetic models for skin. 1. Development Of models , 1998, Journal of pharmaceutical sciences.

[41]  S. Spaan,et al.  Variability of biomarkers in volunteer studies: The biological component. , 2010, Toxicology letters.

[42]  K Krishnan,et al.  A Spreadsheet Program for Modeling Quantitative Structure-Pharmacokinetic Relationships for Inhaled Volatile Organics in Humans , 2005, SAR and QSAR in environmental research.

[43]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[44]  P Delorme,et al.  Physiologically based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapor by humans. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[45]  A. Kramer,et al.  Quantity of ethanol absorption after excessive hand disinfection using three commercially available hand rubs is minimal and below toxic levels for humans , 2007, BMC infectious diseases.

[46]  G. Johanson,et al.  Percutaneous absorption of 2-butoxyethanol vapour in human subjects. , 1991, British journal of industrial medicine.

[47]  R. Tardif,et al.  Physiologically Based Modeling of n-Hexane Kinetics in Humans Following Inhalation Exposure at Rest and Under Physical Exertion: Impact on Free 2,5-Hexanedione in Urine and on n-Hexane in Alveolar Air , 2005, Journal of occupational and environmental hygiene.

[48]  C. Meulenberg,et al.  Empirical relations predicting human and rat tissue:air partition coefficients of volatile organic compounds. , 2000, Toxicology and applied pharmacology.

[49]  P. Strickland,et al.  Polycyclic aromatic hydrocarbon metabolites in urine as biomarkers of exposure and effect. , 1996, Environmental health perspectives.

[50]  Harvey J Clewell,et al.  Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[51]  M. Griffiths.  Introduction to human physiology , 1974 .

[52]  S. Borghoff,et al.  A physiological model for tert-amyl methyl ether and tert-amyl alcohol: hypothesis testing of model structures. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[53]  S. Zorin,et al.  In vitro test of nicotine's permeability through human skin. Risk evaluation and safety aspects. , 1999, The Annals of occupational hygiene.

[54]  E. V. van Lieshout,et al.  Effect of the reduction of skin contamination on the internal dose of creosote workers exposed to polycyclic aromatic hydrocarbons. , 1993, Scandinavian journal of work, environment & health.

[55]  P T Henderson,et al.  1-Hydroxypyrene in urine as a biological indicator of exposure to polycyclic aromatic hydrocarbons in several work environments. , 1988, The Annals of occupational hygiene.

[56]  J. Cocker,et al.  A human exposure study to investigate biological monitoring methods for 2-butoxyethanol , 2003, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[57]  Ginette Truchon,et al.  Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. , 2002, Toxicology letters.

[58]  P T Henderson,et al.  Determination of hydroxylated metabolites of polycyclic aromatic hydrocarbons in urine. , 1987, Journal of chromatography.

[59]  M. Andersen,et al.  Refined PBPK model of aggregate exposure to methyl tertiary-butyl ether. , 2007, Toxicology letters.

[60]  Ian Cousins,et al.  Development and application of a generalized physiologically based pharmacokinetic model for multiple environmental contaminants , 2003, Environmental toxicology and chemistry.

[61]  M E Andersen,et al.  Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment. , 1994, Environmental health perspectives.

[62]  G. Searle,et al.  APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN HUMAN PLASMA , 2006, Drug Metabolism and Disposition.

[63]  Jörg Lippert,et al.  From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools , 2005, Expert opinion on drug metabolism & toxicology.

[64]  P. Mutanen,et al.  Significance of dermal and respiratory uptake in creosote workers: exposure to polycyclic aromatic hydrocarbons and urinary excretion of 1-hydroxypyrene. , 1995, Occupational and environmental medicine.

[65]  C. Thompson,et al.  Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. , 2008, Regulatory toxicology and pharmacology : RTP.

[66]  M. Blaszkewicz,et al.  Human volunteer study on the inhalational and dermal absorption of N-methyl-2-pyrrolidone (NMP) from the vapour phase , 2007, Archives of Toxicology.

[67]  J. DeJongh,et al.  A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans , 1997, Archives of Toxicology.

[68]  W. T. Berge,et al.  A simple dermal absorption model: derivation and application. , 2009 .

[69]  A. Peters,et al.  Associations between mortality and air pollution in central Europe. , 2000, Environmental health perspectives.